Title: Pseudo alteration of Coagulation Profile- In vivo Biochemical reactionary effect of Fresh Frozen Plasma after Infusion

Authors: Dr C.S. Chhatrasal, Dr A. Gandhi, Dr P. Shinde

 DOI:  https://dx.doi.org/10.18535/jmscr/v6i3.14

Abstract

Aims & Objective: The use of fresh frozen plasma (FFP) continues to rise, despite the fact that the supply of plasma derived from allogenic blood donation is finite. The safety and effectiveness of transfusion depend on the appropriate clinical use of blood and blood products. This study was evaluated of coagulation profile in various common disease conditions and conducted to review the effect of FFP transfusion on coagulation profile (INR).

Methodology: A retrospective study of blood bank records and coagulation profile results of the patients given FFP from September 2006 to August 2007, in Gandhi Medical College and Hospital, Bhopal was undertaken. The criteria set by the department of pathology were used as the guidelines.

Results: Total 1064 coagulation studies were performed and 481 were deranged results (exclusive of CT-ICU and ICCU patients). Out of that 112 was in pediatric patients 16 patients was non pediatric illness, 105 in emergency medicine, 70 in surgical,177 in medical  11 in gynecologic and 19 was unclassified patients (Burn, orthopedics).Total 874numbers of patients to which FFP were supplied. 1.70 FFP units supplied per patient. Pediatric patients were 345 and 529adult and elderly. An in depth analysis of the rationale behind prescribing FFP to each patient was made. Every possible justification was sought from the clinician for prescribing FFP.

Conclusion: FFP is a vital component of blood, not just a substitute. Although very useful clinico-pharmacologically, FFP also carries potential adverse effects. Clinicians must abide by the rules and guidelines that exist pertaining to its rational usage. A clinician may have a thousand things in mind but the transfusion personnel are more competent in dealing with the use of components. Let the clinicians know about the indications and usage of blood component, particularly FFP. Even if the indication for FFP is clinically valid, suggest the clinician to be wise still in using the component. Stop the practices that may encourage the irrational use of blood products.

Keywords: Fresh Frozen Plasma (FFP), INR categories, Transfusion.

References

  1. Wikipedia, the free encyclopedia; Key Search “Coagulation”;last modified - 24 October 2007.
  2. Adhikary S Das MD, Rebecca Jacob MD. Peri operative tests ohhemostasis and there clinical implications. Indian J Anaesth.2005; 49 (1): 12-16.
  3. Colman RW, Clowes Aw, George JN, Hirsh J, Marder VJ. Overviewof hemostasis. In: Colman RW, Hirsh J, Marder VJ et al, editors.Hemostasis and thrombosis basic principle and clinical practice.4th edition. Philadelphia: JB Lippincott. 2001; 3-16.
  4. Florell, S.R. & Rodgers, G.M. The PT and thependulum. American Journal of Clinical Pathology, 1996; 699-700.
  5. Hirsh, J. &Poller, L. International normalized ratio: Aguide to understanding and correcting its problems. Archives of Internal Medicine.1994; 154: 282-288.
  6. Nichols, W. L. & Bowie, E. J. W. Standardization of theprothrombin time for monitoring orally administered anticoagulant therapy with use of the international normalized ration system. Mayo Clinical Procedure.1983; 68: 897-898.
  7. From Google search “all coagulation” - Laboratory Corporation of America® Holdings and Lexi-Comp Inc.9. Adcock DM, Kressin DC, and Marlar RA, “Effect of 3.2% vs 3.8%Sodium Citrate Concentration on Routine Coagulation Testing,”Am J ClinPathol, 1997, 107(1):105-10.
  8. Reneke J, Etzell J, Leslie S, et al, “Prolonged Prothrombin Timeand Activated Partial Thromboplastin Time Due to Underfilled Specimen Tubes With 109 mmol/L (3.2%) Citrate Anticoagulant,”Am J ClinPathol, 1998, 109(6):754-7.
  9. Brandt JT, Triplett DA, Alving B, et al, “Criteria for the Diagnosisof Lupus Anticoagulants: An Update. On Behalf of theSubcommittee on Lupus Anticoagulant/AntiphospholipidAntibody of the Scientific and Standardization Committee of theISTH,” ThrombHaemost, 1995, 74(4):1185-90.
  10. Jenson R, “The Antiphospholipid Antibody Syndrome,” ClinHemost Rev, 2001, 15(11):1-4.13. Van Cott EM and Laposata M, “Coagulation,” Jacobs DS, OxleyDK, and DeMott WR, eds, Laboratory Test Handbook, Hudson,OH: Lexi-Comp, 2001, 327-58.
  11. Adcock DM, Jensen R, Johns CS, et al, Coagulation Handbook,Austin, TX: Esoterix Coagulation, 2002.
  12. Lazarchuk J, Kizer J. Interaction of fibrinolytic, coagulation andkinin systems and related pathology. In: Pittiglio DH, Sacher RAEds. Clinical Hematology and Fundamentals of Hemostasis.Philadelphia: FA Davis; 1987; 381-391.
  13. O'Shaughnessy DF, Atterbury C, Bolton Maggs P, Murphy M, Thomas D, Yates S, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosuper-natant. Br J Haematol. 2004; 126:11–8.
  14. Department of Health. Guidelines for the Blood Transfusion Services in the London. United Kingdom HMSO; Fresh frozen plasma. Section: 819; 1:50.
  15. Ortel, L.B. International normalized ratio (INR); an improved way to monitor oral anticoagulant therapy. Nurse Practitioner.1995; 20 (9): 15-22.
  16. Lunberg, George D. MD Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets. Fresh-Frozen Plasma, Cryoprecipitate, and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists.  JAMA. 1994; 271:777–81.
  17. Contreras M, Ala FA, Greaves M, Jones J, Levin M, Machin SJ, et al. Guidelines for the use of fresh frozen plasma. British Committee for Standards in Haematology, Working Party of the Blood Transfusion Task Force. Transfus Med. 1992; 2:57-63. 
  18. Shanberge JN, Quattrociocchi-Longe T. Analysis of fresh frozen plasma administration with suggestions for ways to reduce usage. Transfus Med. 1992; 2:189-94.
  19. Prathiba R, Jayaranee S, Ramesh JC, Lopez CG, Vasanthi N. An audit of fresh frozen plasma usage in a tertiary referral center in a developing country. Malays J Pathol. 2001; 22:41-46. 
  20. Wilson K, MacDougall L, Fergusson D, Graham I, Tinmouth A, Hébert PC. The effectiveness of interventions to reduce physician's levels of inappropriate transfusion: What can be learned from a systematic review of the literature. Transfusion. 2002; 42:1224-9. 
  21. Nordhagen R, Conradi M, Dromtorp SM. Pulmonary reaction associated with transfusion of plasma containing anti-5b. Vox Sang. 1986;5:102-8.
  22. Chng WJ, Tan MK, Kuperan P. An audit of fresh frozen plasma usage in an acute general hospital in Singapore. Singapore Med J. 2003;44:574–8.
  23. Thomas E Auble , David McD. Taylor, Edbert B. Hsu, and Donald M Yealy. Evaluation of guidelines for ordering prothrombin time and partial thromboplastin times.AcadEmerg Med. 2002; 9 (6): 567-574.
  24. Abdel -Wahab, Healy B, Dzik W H. effect of fresh frozen plasma on prothrombin time and bleeding in patients with mild coagulation abnormalities. Transfusion. 2005; 45: 141 A.

Corresponding Author

Dr P. Shinde

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.